Curient: "Mokacyclip Shows Potential for Pediatric Brain Tumor Treatment"

Significant Extension of Survival Compared to Control Group in Animal Studies

Mokacyclip (mocaciclib·Q901), a CDK7 inhibitor anticancer drug developed by Curient, a company specializing in innovative drug development, has shown potential as a candidate for pediatric brain tumor treatment.

On the 30th, Curient announced that research findings on pediatric brain tumors using Mokacyclip were presented at the International Society for Pediatric Neuro-Oncology Symposium (ISPNO 2026), which was recently held in Sydney, Australia.

Recent research results on pediatric brain tumors using Mokacy Clip were presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO 2026) held recently in Sydney, Australia. Curient

This study involved participation from the University of Colorado Anschutz Medical Campus and the Morgan Adams Foundation, among others. Professor Jean Mulcahy Levy of the University of Colorado delivered the presentation. Curient, the developer of Mokacyclip, was a joint participant in the research.

The study focused on medulloblastoma and atypical teratoid/rhabdoid tumor (AT/RT), both of which are representative high-risk pediatric brain tumors. The research team highlighted that inhibiting CDK7, which is involved in the activation process of MYC—a transcriptional regulator that promotes cancer growth in these tumors—could suppress tumor growth.

In animal experiments, the group treated with Mokacyclip showed a significantly extended survival period compared to the control group. Notably, the tumor suppression effect was similar to that observed when CDK7 gene expression was directly blocked, confirming the efficacy of the targeted inhibition. Additionally, Mokacyclip reached the brain and central nervous system and demonstrated anticancer effects, with no significant side effects such as weight loss or blood abnormalities observed.

Based on these results, the research team also proposed a clinical investigator-led study to evaluate safety, appropriate dosage, and combination therapies targeting patients with recurrent pediatric brain tumors.

A Curient representative stated, "We expect Mokacyclip to present new treatment possibilities in the field of pediatric brain tumors, where treatment options are limited," and added, "We will continue to verify its therapeutic efficacy through future clinical studies."

This content was produced with the assistance of AI translation services.